Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Along these lines, three independent groups introduced RNP complexes into human B cells that had been pre-activated with a cocktail of cytokines [8–10].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [8]
In the citing paper
“Results from these studies suggested that the efficiency of gene editing correlated with the level of B cell stimulation prior to nucleofection of the RNP complexes.”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [8]
In the citing paper
“Of note, a previous report concluded that activated human B cells are much more amenable to Cas9-mediated gene editing compared to resting B cells with only about 20% knockout efficiency targeting a single gene during quiescence [8].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702
Self-citationDNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks
van Overbeek, M., Capurso, D., Carter, M. M., Thompson, M. S., Frias, E., Russ, C., Reece-Hoyes, J. S., Nye, C., Gradia, S., Vidal, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.037 · Cited by 454
Hultquist, J. F., Schumann, K., Woo, J. M., Manganaro, L., McGregor, M. J., Doudna, J., Simon, V., Krogan, N. J., & Marson, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.080 · Cited by 170
Self-citation
Research works printed but not linked: 28
- Avery, 2008, STAT3 is required for IL-21-induced secretion of IgE from human naive B cells, Blood, 112, 1784, 10.1182/blood-2008-02-142745 · DOI
- Bach, 2017, FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug, JAMA, 318, 1861, 10.1001/jama.2017.15218 · DOI · Paper page
- Cheong, 2016, Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system, Nat. Commun., 7, 10.1038/ncomms10934 · DOI · Paper page
- Chu, 2016, Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL/6 Cas9 transgenic mouse line, Proc. Natl. Acad. Sci. U. S. A., 113, 12514, 10.1073/pnas.1613884113 · DOI · Paper page
- Chu, 2017, CRISPR/Cas9-mediated in vitro mutagenesis in GC-like B cells, Methods Mol. Biol., 1623, 135, 10.1007/978-1-4939-7095-7_12 · DOI
- Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
- Deenick, 2013, Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells, J. Exp. Med., 210, 2739, 10.1084/jem.20130323 · DOI · Paper page
- Elgueta, 2009, Molecular mechanism and function of CD40/CD40L engagement in the immune system, Immunol. Rev., 229, 152, 10.1111/j.1600-065X.2009.00782.x · DOI · Paper page
- Granholm, 1992, Autoimmunity, polyclonal B-cell activation and infection, Lupus, 1, 63, 10.1177/096120339200100203 · DOI
- Hasbold, 1998, Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4, Eur. J. Immunol., 28, 1040, 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.0.CO;2-9 · doi:10.1002/(sici)1521-4141(199803)28:03<1040::aid-immu1040>3.0.co;2-9
- Hung, 2017, Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells, Mol. Ther., 26, 456, 10.1016/j.ymthe.2017.11.012 · DOI · Paper page
- Kabadi, 2014, Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector, Nucleic Acids Res., 42, 10.1093/nar/gku749 · DOI · Paper page
- Khan, 2011, AAV-mediated gene targeting methods for human cells, Nat. Protoc., 6, 482, 10.1038/nprot.2011.301 · DOI · Paper page
- Kohm, 2002, B cell receptor- and beta 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells, J. Immunol., 168, 6314, 10.4049/jimmunol.168.12.6314 · DOI
- LeBien, 2008, B lymphocytes: how they develop and function, Blood, 112, 1570, 10.1182/blood-2008-02-078071 · DOI · Paper page
- Lenden Hasse, 2017, Generation and CRISPR/Cas9 editing of transformed progenitor B cells as a pseudo-physiological system to study DNA repair gene function in V(D)J recombination, J. Immunol. Methods, 451, 71, 10.1016/j.jim.2017.08.007 · DOI
- Lin, 2014, Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery, elife, 3, 10.7554/eLife.04766 · DOI · Paper page
- Lombardo, 2014, Genome editing: a tool for research and therapy: targeted genome editing hits the clinic, Nat. Med., 20, 1101, 10.1038/nm.3721 · DOI
- Mackay, 2002, BAFF: a fundamental survival factor for B cells, Nat. Rev. Immunol., 2, 465, 10.1038/nri844 · DOI · Paper page
- Maliszewski, 1993, Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines, Eur. J. Immunol., 23, 1044, 10.1002/eji.1830230510 · doi:10.1002/eji.1830230510
- Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
- Oppermann, 2016, High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells, Blood, 128, 934, 10.1182/blood-2015-12-687814 · DOI · Paper page
- Pinello, 2016, Analyzing CRISPR genome-editing experiments with CRISPResso, Nat. Biotechnol., 34, 695, 10.1038/nbt.3583 · DOI · Paper page
- Richardson, 2016, Non-homologous DNA increases gene disruption efficiency by altering DNA repair outcomes, Nat. Commun., 7, 10.1038/ncomms12463 · DOI · Paper page
- Wiles, 2015, CRISPR-Cas9-mediated genome editing and guide RNA design, Mamm. Genome, 26, 501, 10.1007/s00335-015-9565-z · DOI
- Yang, 2012, Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition, Immunity, 36, 857, 10.1016/j.immuni.2012.02.009 · DOI · Paper page
- Yue, 2017, Engineered epidermal progenitor cells can correct diet-induced obesity and diabetes, Cell Stem Cell, 21, 256, 10.1016/j.stem.2017.06.016 · DOI
- Zhen, 2015, Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus, Gene Ther., 22, 404, 10.1038/gt.2015.2 · DOI · Paper page
Cited by
Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009117 · Cited by 31
Metadata
- Authors
- Wu, C.-A. M., Roth, T. L., Baglaenko, Y., Ferri, D. M., Brauer, P., Zuniga-Pflucker, J. C., Rosbe, K. W., Wither, J. E., Marson, A., & Allen, C. D. C.
- Venue
- Journal of Immunological Methods
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 457
- Pages
- 33-40
- ISSN
- 0022-1759
- Cited by
- 57
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 328 d)
- Funders
- University of California, San Francisco
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R01AI130470)
- Canadian Institutes of Health Research (PJT-148948)
- Howard Hughes Medical Institute
- Pew Charitable Trusts
- Burroughs Wellcome Fund
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.